| For: | Alamoudi JA, Li W, Gautam N, Olivera M, Meza J, Mukherjee S, Alnouti Y. Bile acid indices as biomarkers for liver diseases I: Diagnostic markers. World J Hepatol 2021; 13(4): 433-455 [PMID: 33959226 DOI: 10.4254/wjh.v13.i4.433] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i4/433.htm |
| Number | Citing Articles |
| 1 |
Huiping Zhou, Yi Huang, Chen Chen, Meiyi Song, Phillip B. Hylemon. Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities. Pharmacological Reviews 2026; 78(2) doi: 10.1016/j.pharmr.2026.100120
|
| 2 |
J. Jose Corbalan, Pranavi Jagadeesan, Karla K. Frietze, Rulaiha Taylor, Grace L. Gao, Grant Gallagher, Joseph T. Nickels. Humanized monoacylglycerol acyltransferase 2 mice develop metabolic dysfunction-associated steatohepatitis. Journal of Lipid Research 2024; 65(12) doi: 10.1016/j.jlr.2024.100695
|
| 3 |
Sayed Obaidullah Aseem, Phillip B. Hylemon, Huiping Zhou. Bile Acids and Biliary Fibrosis. Cells 2023; 12(5) doi: 10.3390/cells12050792
|
| 4 |
Rulaiha Taylor, Veronia Basaly, Bo Kong, Ill Yang, Anita M Brinker, Gina Capece, Anisha Bhattacharya, Zakiyah R Henry, Katherine Otersen, Zhenning Yang, Vik Meadows, Stephanie Mera, Laurie B Joseph, Peihong Zhou, Lauren M Aleksunes, Troy Roepke, Brian Buckley, Grace L Guo. Effects of therapeutically approved individual bile acids on the development of metabolic dysfunction-associated steatohepatitis a low bile acid mouse model. Toxicological Sciences 2024; 202(2) doi: 10.1093/toxsci/kfae110
|
| 5 |
Wenkuan Li, Jawaher Abdullah Alamoudi, Nagsen Gautam, Devendra Kumar, Macro Olivera, Yeongjin Gwon, Sandeep Mukgerjee, Yazen Alnouti, Amal Santra. Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. International Journal of Hepatology 2022; 2022 doi: 10.1155/2022/5473752
|
| 6 |
Harry Sutton, Ronald J. Sokol, Binita M. Kamath. IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?. Hepatology 2025; 82(4) doi: 10.1097/HEP.0000000000001032
|
| 7 |
A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2022; 12(1) doi: 10.1016/j.jceh.2021.08.017
|
| 8 |
Leon Deutsch, Alexandros Sotiridis, Boštjan Murovec, Janez Plavec, Igor Mekjavic, Tadej Debevec, Blaž Stres. Exercise and Interorgan Communication: Short-Term Exercise Training Blunts Differences in Consecutive Daily Urine 1H-NMR Metabolomic Signatures between Physically Active and Inactive Individuals. Metabolites 2022; 12(6) doi: 10.3390/metabo12060473
|
| 9 |
Bandar D. Alrehaili. Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders. Saudi Journal of Gastroenterology 2024; 30(5) doi: 10.4103/sjg.sjg_53_24
|
| 10 |
Rulaiha Taylor, Zhenning Yang, Zakiyah Henry, Gina Capece, Vik Meadows, Katherine Otersen, Veronia Basaly, Anisha Bhattacharya, Stephanie Mera, Peihong Zhou, Laurie Joseph, Ill Yang, Anita Brinker, Brian Buckley, Bo Kong, Grace L Guo. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model. Toxicological Sciences 2024; 199(2) doi: 10.1093/toxsci/kfae029
|
| 11 |
Irene Díaz-Alberola, Daniel E. Di Zeo-Sánchez, Vanesa Garrido-Rodríguez, Carlos López-Gómez, Cristina Rodríguez-Díaz, Raul J. Andrade, M. Isabel Lucena, Marina Villanueva-Paz, Eduardo García-Fuentes. The gut–liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system. Acta Pharmaceutica Sinica B 2026; doi: 10.1016/j.apsb.2026.04.014
|
| 12 |
Zakiyah R Henry, Syeda Maliha, Veronia Basaly, Zhenning Yang, Rulaiha E Taylor, Katherine Otersen, Vik Meadows, Daniel Rizzolo, Mary Stofan, Anisha Bhattacharya, Peihong Zhou, Anita Brinker, Ill Yang, Lanjing Zhang, Laurie B Joseph, Brian Buckley, Bo Kong, Grace L Guo. Ursodeoxycholic acid acts as an ileal FXR agonist in male mice with hepatic deficiency of FXR. eGastroenterology 2025; 3(3) doi: 10.1136/egastro-2025-100227
|
| 13 |
Ahmed Ghallab, Mattias Mandorfer, Guido Stirnimann, Joachim Geyer, Erik Lindström, Tom Luedde, Schalk van der Merwe, Jassin Rashidi-Alavijeh, Hartmut Schmidt, Saul J. Karpen, Peter Fickert, Michael Trauner, Jan G. Hengstler, Paul A. Dawson. Enteronephrohepatic circulation of bile acids and therapeutic potential of systemic bile acid transporter inhibitors. Journal of Hepatology 2025; 83(5) doi: 10.1016/j.jhep.2025.05.009
|
| 14 |
Gopanandan Parthasarathy, Harmeet Malhi, Jasmohan S. Bajaj. Therapeutic manipulation of the microbiome in liver disease. Hepatology 2026; 83(4) doi: 10.1097/HEP.0000000000000987
|
| 15 |
Matthias Grimmler, Tobias Frömel, Angelique Masetto, Holger Müller, Tina Leber, Christoph Peter. Performance evaluation of enzymatic total bile acid (TBA) routine assays: systematic comparison of five fifth-generation TBA cycling methods and their individual bile acid recovery from HPLC-MS/MS reference. Clinical Chemistry and Laboratory Medicine (CCLM) 2025; 63(4) doi: 10.1515/cclm-2024-1029
|
| 16 |
Maria J. Monte, Thi Dong-Binh Tran, Jane I. Grove, Dingzhou Li, Camilla Stephens, M. Isabel Lucena, Raúl J. Andrade, Sabine Weber, Alexander Gerbes, Einar S. Bjornsson, Guido Stirnimann, Helgi K. Bjornsson, Ann K. Daly, Anthony Evans, Shashi K. Ramaiah, Sara A. Paciga, Melanie Lingaya, Edmond Atallah, Mercedes Robles-Diaz, Sophia L. Samodelov, Oliver Poetz, William Rosenberg, John Ramage, Andrew Fowell, William J.H. Griffiths, Matthew E. Cramp, Janisha Patel, Ahmed M. Elsharkawy, Jose J.G. Marin, Gerd A. Kullak-Ublick, Guruprasad P. Aithal. Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury. eBioMedicine 2026; 126 doi: 10.1016/j.ebiom.2026.106229
|
| 17 |
Jie Li, Xiaolong Lian, Baojian Li, Quhuan Ma, Lingling Yang, Guangmiao Gao, Tingmei Yin, Xiaoyan Fu, Yi Deng, Zhijun Yang, Xiujuan Yang. Pharmacodynamic material basis of licorice and mechanisms of modulating bile acid metabolism and gut microbiota in cisplatin-induced liver injury based on LC-MS and network pharmacology analysis. Journal of Ethnopharmacology 2025; 340 doi: 10.1016/j.jep.2024.119293
|
| 18 |
M. Schauermann, R. Wang, J. Pons-Kuehnemann, M.F. Hartmann, T. Remer, Y. Hua, A. Bereket, M. Wasniewska, M. Shmoish, Z. Hochberg, A. Gawlik, S.A. Wudy. Targeted quantitative analysis of urinary bile acids by liquid chromatography-tandem mass spectrometry: Method development and application to healthy and obese children. The Journal of Steroid Biochemistry and Molecular Biology 2025; 249 doi: 10.1016/j.jsbmb.2025.106712
|
| 19 |
Veronia Basaly, Zakiyah R. Henry, Rulaiha E. Taylor, Bo Kong, Ill Yang, Anita Brinker, Zhenning Yang, Peihong Zhou, Laurie B. Joseph, Lauren Aleksunes, Brian Buckley, Masahiko Negishi, Grace L. Guo. Mutation of PXR phosphorylation motif at Ser347 disrupts lipid and bile acid homeostasis in diet-induced metabolic dysfunction–associated steatohepatitis in mice. Drug Metabolism and Disposition 2026; 54(2) doi: 10.1016/j.dmd.2025.100222
|
| 20 |
Han Hu, Salim Jamil, Muhammad Bilal Azmat, Mohammed Alissa, Ghfren S. Aloraini, Amal A. Albati, Ahmed Al-Emam, Hesham M. Hassan. Tapentadol induces progressive hepatic damage via disrupting Hippo–YAP and bile acid–FXR pathways: An integrated experimental and computational perspective. Tissue and Cell 2026; 100 doi: 10.1016/j.tice.2026.103362
|